404 completed. 404 Phase 3, 74 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 404 | Completed 404 |
| Phase 2 | 74 | Completed 74 |
Follow Behavioral Symptoms: new trials by email Literature Review of Behavioral Symptoms trials Research Report on Behavioral Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" CYB003, Psychological Support, Placebo - Major Depressive Disorder | Phase 3 | Completed | Cybin IRL Limited | 223 | 2024-12-17 | 2026-10-27 |
| MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva Cannabis Sativa Oil, Placebo - Dementia with Behavioral Disturbance | Phase 2 / Phase 3 | Completed | Fondation pour l'accueil et l'hébérement des personnes âgées | 27 | 2023-09-29 | 2024-12-17 |
| OptimizeD Pilot Study Healthy Activity Program (HAP), Antidepressant medication (ADM) - Depression, Depressive Disorder | Phase 3 | Completed | Harvard Medical School (HMS and HSDM) | 76 | 2023-08-01 | 2024-04-09 |
| Long-term Efficacy of Pramipexole in Anhedonic Depression Pramipexole - Anhedonia, Depression | Phase 3 | Completed | Region Skane | 55 | 2023-04-21 | 2026-04-28 |
| Acceptance Commitment Therapy for Caregivers of People with Memory Loss Acceptance and Commitment Therapy - Caregiver Burden, Behavioral and Psychiatric Symptoms of Dementia | Phase 3 | Completed | Utah State University | 121 | 2023-02-16 | 2024-12-06 |
| Pramipexole for Anhedonic Depression Pramipexole, Placebo - Psychiatric Disorders Mood, Anhedonia | Phase 3 | Completed | Region Skane | 85 | 2023-02-08 | 2026-04-28 |
| Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) BXCL501, Matching Placebo - Agitation,Psychomotor, Bipolar I Disorder | Phase 3 | Completed | BioXcel Therapeutics Inc | 452 | 2022-11-21 | 2026-08-07 |
| Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents Ketamine Hydrochloride, Midazolam Hydrochloride - Suicide, Attempted, Suicide and Depression | Phase 3 | Completed | University of Texas Southwestern Medical Center | 50 | 2022-10-03 | 2026-10-15 |
| THRIVE Feasibility Trial Anesthetic technique Propofol TIVA, Anesthetic technique inhaled agent - Surgery--Complications, Anesthesia Complication | Phase 3 | Completed | Washington University School of Medicine | 300 | 2022-09-29 | 2023-11-24 |
| Treating Immuno-metabolic Depression With Anti-inflammatory Drugs Celecoxib 400mg, Placebo - Depressive Disorder, Major, Inflammation | Phase 3 | Completed | Amsterdam UMC, location VUmc | 94 | 2022-09-28 | 2026-09-21 |
| A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation AXS-05, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Completed | Axsome Therapeutics, Inc. | 408 | 2022-09-06 | 2026-08-13 |
| NRX-101 for Bipolar Depression With Subacute Suicidal Ideation NRX-101, Lurasidone HCl - Bipolar Depression, Suicidal Ideation and Behavior | Phase 2 / Phase 3 | Completed | NeuroRx, Inc. | 74 | 2022-05-12 | 2024-05-08 |
| Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II) BXCL501, Matching Placebo - Agitation, Dementia | Phase 3 | Completed | BioXcel Therapeutics Inc | 151 | 2022-04-27 | 2026-08-11 |
| Frontline Clinician Psilocybin Study Psilocybin (Usona Institute), Active placebo - Burnout, Caregiver, Burnout, Professional | Phase 3 | Completed | University of Washington | 30 | 2022-03-03 | 2025-03-18 |
| A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation AXS-05 (dextromethorphan-bupropion), Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Completed | Axsome Therapeutics, Inc. | 456 | 2021-06-17 | 2025-12-08 |
| Electro-Magnetic Convulsive Therapies for Depression: a Non-inferiority Study Magnetic Seizure Therapy, Electroconvulsive Therapy - Major Depressive Disorder, Bipolar Depression | Phase 2 / Phase 3 | Completed | University of Sao Paulo | 100 | 2021-05-31 | 2026-09-29 |
| Efficacy of Adaptogens in Patients With Long COVID-19 ADAPT-232 oral solution, Placebo oral solution - Covid19 | Phase 2 / Phase 3 | Completed | Swedish Herbal Institute AB | 100 | 2021-04-19 | 2021-12-28 |
| A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder PRAX-114, Placebo - Major Depressive Disorder | Phase 2 / Phase 3 | Completed | Praxis Precision Medicines | 216 | 2021-03-30 | 2022-07-21 |
| Antidepressants Trial in Parkinson's Disease Nortriptyline, Escitalopram, Placebo - Depression, Parkinson Disease | Phase 3 | Completed | University College, London | 52 | 2021-03-05 | 2023-05-06 |
| Esketamine and Perioperative Depressive Symptoms Esketamine, Normal saline - Depressive Symptoms, Esketamine | Phase 2 / Phase 3 | Completed | Beijing Tiantan Hospital | 435 | 2021-02-19 | 2025-08-01 |
Showing 20 of 404. Sign in to see all of them.
Depression (327) · Depressive Disorder, Major (137) · Depressive Disorder (48) · Psychomotor Agitation (37) · Anxiety Disorders (32) · Alzheimer Disease (24) · Bipolar Disorder (24) · Stress Disorders, Post-Traumatic (16) · Dementia (15) · Mental Disorders (15) · Mood Disorders (15) · Psychotic Disorders (15) · Schizophrenia (10) · Suicidal Ideation (10) · Aggression (9)
Behavior (401) · Mental Disorders (284) · Mood Disorders (168) · Depressive Disorder (113) · Pathological Conditions, Signs and Symptoms (85) · Nervous System Diseases (76) · Signs and Symptoms (76) · Neurologic Manifestations (66) · Neurobehavioral Manifestations (51) · Aberrant Motor Behavior in Dementia (45) · Central Nervous System Diseases (40) · Brain Diseases (38) · Dyskinesias (37) · Neurocognitive Disorders (37)
Escitalopram (24) · Sertraline (18) · Vortioxetine (14) · Cognitive Behavioral Therapy (12) · Paroxetine (12) · Duloxetine Hydrochloride (10) · Fluoxetine (10) · SR 48968 (10) · Venlafaxine Hydrochloride (10) · Amibegron hydrochloride (8) · Citalopram (8) · Aripiprazole (7) · Dexmedetomidine (7) · Docosahexaenoic Acids (7) · Quetiapine Fumarate (7)
Sanofi (18) · Otsuka Pharmaceutical Development & Commercialization, Inc. (15) · AstraZeneca (14) · Forest Laboratories (14) · Wyeth is now a wholly owned subsidiary of Pfizer (13) · Takeda (10) · Axsome Therapeutics, Inc. (7) · University of Pennsylvania (7) · University of Pittsburgh (7) · GlaxoSmithKline (6) · Massachusetts General Hospital (6) · University of Washington (6) · Corcept Therapeutics (5) · Medical University of South Carolina (5) · Pfizer (5)
United States (254) · Canada (42) · France (33) · Germany (26) · Poland (22) · Russia (21) · Serbia (19) · Ukraine (19) · United Kingdom (18) · Bulgaria (17) · Croatia (16) · Romania (16) · South Africa (16) · Puerto Rico (15) · Australia (14)
Carl Gommoll, MS (5) · Katherine Beebe, PhD (5) · David Mischoulon, MD, PhD (4) · Sanjeev Pathak, MD (4)
PMID 34817851, PMID 31577867, PMID 24067192, PMID 24816198, PMID 26474010, PMID 26644957, PMID 30508090, PMID 33884617, PMID 36708956, PMID 37656180, PMID 40681915, PMID 41533472, PMID 41961243, PMID 23485955, PMID 23497790, PMID 24175720, PMID 24571916, PMID 25080392, PMID 25758058, PMID 26644956, PMID 26709542, PMID 29140227, PMID 29523415, PMID 34183490, PMID 37099968, PMID 38421922, PMID 39108660, PMID 40607746, PMID 40852147, PMID 41055581, PMID 41591746, PMID 20732631, PMID 21731831, PMID 22027845, PMID 23673347, PMID 24138011, PMID 24507016, PMID 25272149, PMID 25602163, PMID 25980552, PMID 27208498, PMID 29163985, PMID 30419989, PMID 31708380, PMID 31818787, PMID 31969269, PMID 32942346, PMID 33546709, PMID 33677183, PMID 33915374
2008 (8), 2017 (4), 2009 (3), 2016 (3), 2004 (2), 2014 (2), U19MH098780 (2), 1RC2AG036535 (1), 2015 (1), F32MH075583 (1), I01CX000217 (1), K02MH001938 (1), R01AG031348 (1), R01AR044724 (1), R01AT000001 (1)